ResultsIQ

ResultsIQ › Latest results › Orchid Pharma Limited

Orchid Pharma Limited Q2 FY26 results deck summary

NSE: ORCHPHARMA · BSE: 524372

Results deck of 11 Nov 2025, summarised by AI from the filing.

Q2 FY26 sales fell 13% to ₹194 cr and PAT fell 92% to ₹2 cr, with EBITDA margin at 8%.

Key takeaways

  1. Sales Q2-26 sales ₹194 cr (Q2-25: ₹223 cr, -13%); H1-26 ₹366 cr (H1-25: ₹467 cr, -22%).
  2. EBITDA Q2-26 EBITDA ₹15 cr (Q2-25: ₹38 cr, -61%); H1-26 ₹44 cr (H1-25: ₹79 cr, -44%).
  3. PAT Q2-26 PAT ₹2 cr (Q2-25: ₹26 cr, -92%); H1-26 ₹20 cr (H1-25: ₹55 cr, -64%).
  4. Gross margin Q2-26 gross margin 32% of sales, down from 41% in Q2-25.
  5. Other income Q2-26 other income ₹15 cr (Q2-25: ₹8 cr, +88%); H1-26 ₹31 cr (H1-25: ₹16 cr, +94%).

Original filing on BSE

Orchid Pharma Limited Q1 FY27 results

As filed: Revenue ₹304 cr (+76% year on year), EBITDA ₹14.0 cr (−7% year on year), PAT ₹3.2 cr (−79% year on year), EBITDA margin 4.6% (−407 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹368 cr (+55% year on year), EBITDA ₹30.2 cr (+8% year on year), PAT ₹25.8 cr (+17% year on year), EBITDA margin 8.2% (−363 bps). Score 66 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were in line with it. EBITDA margin fell 363 bps year on year. Other income 31% of PBT. Tax rate 0%. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +38.9% in 30 days (Nifty 500: +0.9%).
  • Q3 FY26: Revenue ₹207 cr (−4% year on year), EBITDA ₹1.6 cr (−94% year on year), PAT −₹12.6 cr (−123% year on year), EBITDA margin 0.8% (−1,000 bps). Score 20 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit before exceptional items growth were well below it. EBITDA margin fell 1000 bps year on year. Share price after the results: −25.8% in 30 days (Nifty 500: −10.1%).
  • Q2 FY26: Revenue ₹194 cr (−13% year on year), EBITDA −₹1.0 cr (−103% year on year), PAT −₹6.0 cr (−122% year on year), EBITDA margin -0.5% (−1,000 bps). Score 20 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 1000 bps year on year. Profit fell 140% from last quarter. Share price after the results: +0.6% in 30 days (Nifty 500: −0.2%).
  • Q1 FY26: Revenue ₹173 cr (−29% year on year), EBITDA ₹15.0 cr (−53% year on year), PAT ₹15.0 cr (−48% year on year), EBITDA margin 8.7% (−444 bps). Score 7 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was below it. EBITDA margin fell 444 bps year on year. Other income 79% of PBT. Tax rate 0%. Revenue fell 27% from last quarter. Share price after the results: −7.0% in 30 days (Nifty 500: +2.4%).
  • Q4 FY25: Revenue ₹237 cr (+9% year on year), EBITDA ₹28.0 cr (0% year on year), PAT ₹22.0 cr (−33% year on year), EBITDA margin 11.8% (−109 bps). Score 34 of 100, Below trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin fell 109 bps year on year. Tax rate 0%. Share price after the results: −5.1% in 30 days (Nifty 500: +1.7%).
  • Q3 FY25: Revenue ₹217 cr (−2% year on year), EBITDA ₹27.0 cr (−23% year on year), PAT ₹21.0 cr (−28% year on year), EBITDA margin 12.4% (−339 bps). Score 13 of 100, Below trend. Revenue growth was well below the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 339 bps year on year. Other income 36% of PBT. Tax rate 0%. Profit fell 22% from last quarter.
  • Q2 FY25: Revenue ₹223 cr (+12% year on year), EBITDA ₹30.0 cr (+25% year on year), PAT ₹27.0 cr (+35% year on year), EBITDA margin 13.5% (+139 bps). Score 55 of 100, In line with trend. EBITDA margin rose 139 bps year on year. Other income 31% of PBT. Tax rate 0%. Not enough history for a trend yet: scored on growth alone. Revenue fell 9% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Orchid Pharma Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.